Market News & Trends
Scientific Posters at BPI Spotlight Cutting-Edge Research
— 2015 BioProcess International Conference & Expo Unveils Over 100 Peer-Submitted Scientific Posters Featuring Innovative Concepts and Solutions…
Zealand Meets Development Milestone in Collaboration With Boehringer Ingelheim
Zealand recently announced that Boehringer Ingelheim has selected a novel peptide therapeutic to be advanced into preclinical development under one of two ongoing collaboration agreements…
Opsonix is Launched to Develop Pathogen-Extracting Therapy
Opsonix, Inc. recently announced the company’s launch with an $8-million Series A financing to develop a pathogen-extracting therapy designed to remove infectious pathogens and toxins…
Codexis Earns $6.5-Million Milestone From GSK
Codexis, Inc. recently announced it successfully completed Wave 2 of the transfer of its proprietary CodeEvolver protein engineering platform technology to GlaxoSmithKline (GSK) in the…
Emisphere Signs Lucrative License Agreement With Novo Nordisk
Emisphere Technologies, Inc. recently announced it has entered into a Development and License Agreement with Novo Nordisk A/S to develop and commercialize oral formulations of…
Realizing Process Innovation in Aseptic Manufacturing: An Improved RABS Concept
(Bio-)pharmaceutical service providers in their role of manufacturing complex drug products face a difficult challenge in providing reliable and repeatable aseptic processes for ever-decreasing batch…
Astellas Pharma & Immunomic Therapeutics Announce $300-Million Worldwide Partnership for LAMP-vax Products
Immunomic Therapeutics, Inc. and Astellas Pharma Inc. recently announced they have entered into an exclusive worldwide license agreement to the LAMP-vax products for the treatment…
Ergomed Significantly Increases Contribution in CEL-SCI’s Phase III Trial
CEL-SCI Corporation and its Clinical Research Organization (CRO) Ergomed plc recently announced they have expanded their co-development agreement with increased activities to be undertaken by…
Enable Injections Introduces Mobile Monitoring & Larger Volume Capabilities to its Wearable Injectors
Enable Injections, the developer and manufacturer of a new wearable injector technology platform that allows patients to comfortably and easily self-administer large volume drugs subcutaneously,…
Capsugel Expands Its Successful DRcaps Capsule Platform With New Liquid-Fill Capability
Capsugel recently announced it has developed a technology that makes its vegetarian, acid-resistant DRcaps hard capsules suitable for liquid-fill applications. As a result, Capsugel’s customers…
Baxalta & Momenta Announce Initiation of Pivotal Clinical Trial for Biosimilar
Baxalta Incorporated and Momenta Pharmaceuticals, Inc. recently announced the initiation of a pivotal clinical trial in patients with chronic plaque psoriasis for M923, a biosimilar…
Merck Millipore Adds Protein Pegylation to Portfolio of Services Through Collaboration
Merck Millipore recently announced a collaboration with celares GmbH to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The new service offering enabled…
PharmaCyte Biotech’s Encapsulation Technology Could Address Unmet Medical Need
PharmaCyte Biotech, Inc. recently announced the second in a series of articles that will serve to educate the public on its technology and how it…
Hemispherx Biopharma Receives New Composition of Matter Patent
Hemispherx Biopharma, Inc. recently announced it received formal notice on September 21, 2015, that the European Patent Office's Examining Division granted the Company's application titled…
Cellectar Biosciences Announces Pricing of $3.3 Million Financing
Cellectar Biosciences, Inc. recently announced the pricing of a registered direct offering of 1,017,272 shares of its common stock and Series B pre-funded warrants to…
AAA Announces Positive Results From Phase III Study
Advanced Accelerator Applications S.A. recently announced that the pivotal Phase III NETTER-1 study for Lutathera (177Lu-DOTATATE) met its primary endpoint of assessing progression-free survival (PFS),…
Bayer Receives FDA Approval for First & Only Electronic Autoinjector in RRMS Treatment
Bayer HealthCare recently announced the US FDA approved BETACONNECT, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). BETACONNECT will…
Genisphere Closes $4 Million for Expansion of 3DNA Targeted Drug Delivery Platform
Genisphere LLC recently announced it has closed a $4-million equity round. This round of fundraising will extend and expand development of Genisphere's targeted drug delivery…
Vetter Embarks on a 300 Million Euro Investment Strategy
Ravensburg, Germany, September 30, 2015 – Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug…
Ultra-Low Flow Technology for Drug Delivery
FARMINGTON, CT (September 2015) – Mott Corporation has developed a technology that controls the flow rate of a liquid or drug in devices over…
